Financial reports
10-Q
2024 Q2
Quarterly report
13 Aug 24
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
10-K
2023 FY
Annual report
19 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
18 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
Current reports
8-K
Enrollment open for patients with LN; enrollment in SLE, SSC, and AAV expected to open in the fourth quarter of 2024
30 Sep 24
8-K
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
19 Sep 24
8-K
Other Events
10 Sep 24
8-K
Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
19 Aug 24
8-K
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
13 Aug 24
8-K
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
8 Jul 24
8-K
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
24 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
8-K
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
5 Jun 24
8-K
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
14 May 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Mar 24
S-8
Registration of securities for employees
19 Mar 24
424B5
Prospectus supplement for primary offering
24 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 23
S-8
Registration of securities for employees
9 Aug 23
S-8
Registration of securities for employees
15 Mar 23
424B5
Prospectus supplement for primary offering
8 Nov 22
S-3/A
Shelf registration (amended)
16 Mar 22
Proxies
DEFR14A
Revised proxy
26 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
DEF 14A
Definitive proxy
18 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
18 Mar 21
DEF 14A
Definitive proxy
18 Mar 21
Other
EFFECT
Notice of effectiveness
10 May 22
CORRESP
Correspondence with SEC
5 May 22
UPLOAD
Letter from SEC
16 Mar 22
EFFECT
Notice of effectiveness
24 May 21
CORRESP
Correspondence with SEC
19 May 21
UPLOAD
Letter from SEC
18 May 21
EFFECT
Notice of effectiveness
31 Mar 21
CORRESP
Correspondence with SEC
26 Mar 21
UPLOAD
Letter from SEC
18 Mar 21
EFFECT
Notice of effectiveness
21 Aug 20
Ownership